Gedeon Richter Polskasp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-11-12
Share capital
145 000 000,00 PLN
Registered address
Ks. J.poniatowskiego 5, 05-825 Grodzisk Mazowiecki, Poland
Electronic delivery address
AE:PL-65593-72841-CSWRG-20

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 35 days early. All were audited by a statutory auditor.

  • 202517/06/2026
  • 202423/06/2025
  • 202320/06/2024
  • 202223/06/2023
  • 202105/07/2022
  • 202007/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 104.07mMedianUSD 917.74kAverageUSD 25.73m
Net profit
This companyUSD 1.54mMedianUSD 14.44kAverageUSD 2.75m
Operating costs
This companyUSD 98.80mMedianUSD 860.03kAverageUSD 21.34m
Assets
This companyUSD 118.22mMedianUSD 883.09kAverageUSD 31.39m

Public procurement

Gedeon Richter Polska is the contractor in one public sector contract, worth USD 3.32k.

SubjectAmount
Accommodation service for pensioners and disability pensioners from Karsin
$3,323

Trademarks

Gedeon Richter Polska holds 64 active trademarks registered with the Polish Patent Office. 29 marks have expired or were not registered. The first mark was filed in 1962.

MarkNumberClassesStatusProtected until
ZDROWA ONAZ.55546535, 41, 42, 44Protected Apr 28, 2033
EFEKTAN ZAPOBIEGANIE I LECZENIE NUDNOŚCI ORAZ WYMIOTÓW DLA DOROSŁYCH I DZIECI POWYŻEJ 6 ROKU ŻYCIA 5 SASZETEK DO BEZPOŚREDNIEGO SPOŻYCIAZ.5411965Protected Mar 25, 2032
EFEKTAN MAX ZAPOBIEGANIE I LECZENIE NUDNOŚCI ORAZ WYMIOTÓW DLA DOROSŁYCH I DZIECI POWYŻEJ 6 ROKU ŻYCIA 5 SASZETEK DO BEZPOŚREDNIEGO SPOŻYCIAZ.5411975Protected Mar 25, 2032
EFEKTANZ.5411985Protected Mar 25, 2032
EFEKTAN MAXZ.5411995Protected Mar 25, 2032
MarkProtected until
ZDROWA ONAApr 28, 2033
EFEKTAN ZAPOBIEGANIE I LECZENIE NUDNOŚCI ORAZ WYMIOTÓW DLA DOROSŁYCH I DZIECI POWYŻEJ 6 ROKU ŻYCIA 5 SASZETEK DO BEZPOŚREDNIEGO SPOŻYCIAMar 25, 2032
EFEKTAN MAX ZAPOBIEGANIE I LECZENIE NUDNOŚCI ORAZ WYMIOTÓW DLA DOROSŁYCH I DZIECI POWYŻEJ 6 ROKU ŻYCIA 5 SASZETEK DO BEZPOŚREDNIEGO SPOŻYCIAMar 25, 2032
EFEKTANMar 25, 2032
EFEKTAN MAXMar 25, 2032

Authorized Representatives

Aneta Grzegorzewska – Attorney-in-fact (joint)
Jan Władysław Warejko – Attorney-in-fact (joint)
Krzysztof Lonca – Attorney-in-fact
Mariusz Roman Mańkowski – Członek
Renata Pawlak Morka – Attorney-in-fact (joint)

Manner of representation

The President of the Management Board and the Vice-President are authorised to represent the company independently. Other members of the management board are authorised to represent the company jointly with another member of the management board or a commercial proxy. Commercial proxies are authorised to represent the company jointly with a member of the management board.

Supervisory board

Attila Szénási – Supervisory Board Member
Bence Kovács – Supervisory Board Member
Dóra Fülöp – Supervisory Board Member
Katalin Éva Erdei – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2002-09-12.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$134.8K
Buildings and premises
$11.9M

MSiG notices

Publication dateEvent
Jan 16, 2013Call to creditors

Public aid

10 public aid cases recorded, with a total value of $1,281,591.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–
De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)
–

European Funds

ProjectEU co-financing
Development of a manufacturing technology for a generic drug used in the treatment of hyperuricaemia, based on an active substance in a new polymorphic crystalline form
$312.8K
Expansion of the Gedeon Richter research and development laboratory by establishing a unit specialising in the development of innovative methods for producing active substances in nanoparticle form
$227K

Regulatory authorisations

AuthorityTypeStatus
Waste generation Active

Change history

DateEvent
2025-08-04PKD change
2018-10-02PKD change
2016-08-09PKD change
2015-03-03PKD change
2014-05-21PKD change

FAQ

Last updated: 2026-10-07